Are you Dr. Pryma?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Philadelphia, PA 19104Phone+1 215-579-1300Fax+1 215-662-7011
Summary
- Dr. Daniel Pryma, MD is a board certified nuclear medicine physician in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, Florida, and New Jersey. He is affiliated with Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and Philadelphia Veterans Affairs Medical Center.
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 2003 - 2005
Loyola University Medical CenterInternship, Internal Medicine, 2002 - 2003
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
NJ State Medical License 2014 - 2025
PA State Medical License 2005 - 2024
FL State Medical License 2014 - 2022
NY State Medical License 2003 - 2016
IL State Medical License 2002 - 2003- American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Start of enrollment: 2009 Jun 04
- FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
- FDG PET/CT in Lung Cancer Staging Start of enrollment: 2016 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPrimary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using MidtreatmentF-Fluorodeoxyglucose Posi...Feng-Ming Spring Kong, Chen Hu, Daniel A Pryma, Fenghai Duan, Martha Matuszak
Journal of Clinical Oncology. 2024-11-20 - 1767 citationsRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerChristina Twyman-Saint Victor, Andrew J. Rech, Amit Maity, Ramesh Rengan, Kristen E. Pauken
Nature. 2015-04-16 - 14 citationsHow Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy.David A. Mankoff, Michael D. Farwell, Amy S. Clark, Daniel A. Pryma
Cancer Journal. 2015-05-01
Authored Content
- A Bright Future for Nuclear MedicineNovember 2018
Press Mentions
Neuroendocrine Cancer Program: Not a Rare Cancer at Penn MedicineOctober 4th, 2021- Awards & Accolades: May 2021June 9th, 2021
Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (Iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or ParagangliomaSeptember 17th, 2018- Join now to see all
